Toggle navigation
Home
About us
Challenge
Members
Our Members
Associated Members
Join us
Pipeline
News
Events
Contact us
My cart
Sign in
Prev
1
2
Next
BEAM Alliance News
EU-JAMRAI: BEAM Alliance becomes a new stakeholder
BEAM Alliance, BEAM Alliance
—
April 2018
— 35 views
Antibiotic resistance: Nosopharm and the University of Illinois at Chicago describe mechanism of action of new class of antibiotics in Molecular Cell
NOSOPHARM
—
April 2018
— 9 views
Combioxin Announces Completion of CAL02 FIM Trial in Patients with Severe Pneumococcal Pneumonia
Combioxin SA
—
March 2018
— 55 views
Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin – a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia
Polyphor Ltd
—
March 2018
— 15 views
Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to treat complicated Urinary Tract Infections (cUTI)
ALLECRA THERAPEUTICS
—
March 2018
— 16 views
First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program
ANTABIO S.A.S
—
March 2018
— 11 views
The BEAM Alliance is speaking at the 10th Community of Users Meeting - Health session "Preparedness and response to Infectious Disease Threats" in Brussels
BEAM Alliance, BEAM Alliance
—
March 2018
— 52 views
Basilea reports clinical phase 3 study start with antibiotic ceftobiprole in skin infections under BARDA contract
Basilea Pharmaceutica International Ltd.
—
February 2018
— 34 views
Debiopharm continues the fight against antibiotic resistance with investment in ABAC Therapeutics Inc.
Debiopharm International
—
February 2018
— 24 views
Dossier Antibiothérapie - Thérapie antibactérienne
BEAM Alliance, BEAM Alliance
—
February 2018
— 41 views
Dossier Antibiothérapie - Menace bactérienne
BEAM Alliance, BEAM Alliance
—
February 2018
— 38 views
Dossier Antibiothérapie - Incitations à l’investissement
BEAM Alliance, BEAM Alliance
—
February 2018
— 27 views
Polyphor: Global No. 2 in the 2018 Biopharmaceuticals Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation
Polyphor Ltd
—
January 2018
— 22 views
Results of Clinical Trial for DAV132 Published in JID
DA VOLTERRA
—
January 2018
— 257 views
The first major scientific article on the antimicrobial peptide SAAP-148 appeared today in Science Translational Medicine.
Madam Therapeutics BV
—
January 2018
— 154 views
Madam Therapeutics received an award in the NECTAR program
Madam Therapeutics BV
—
December 2017
— 159 views
BioVersys AG successfully closes Series A2 financing round
BioVersys AG
—
November 2017
— 145 views
Da Volterra is a partner in the new COMBACTE-CDI consortium
DA VOLTERRA
—
November 2017
— 93 views
November 16th, 2017: New BEAM Alliance Position Paper calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance
BEAM Alliance, BEAM Alliance
—
November 2017
— 1080 views
AiCuris Announces that its Licensee MSD Received Positive CHMP Opinion for PREVYMIS™ (Letermovir) Recommending Approval in Europe
AiCuris Anti-infective Cures GmbH
—
November 2017
— 156 views
Improving the fate of severely infected patients: the promise of anti-toxin treatments and superiority trials
Combioxin SA
—
November 2017
— 121 views
Mutabilis joins the European ENABLE consortium to fight antibiotic resistance
Mutabilis SAS
—
October 2017
— 155 views
ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections
ANTABIO S.A.S
—
October 2017
— 180 views
Eligo Bioscience Secures $20 Million Series A from Khosla Ventures and Seventure to Bring Precision Medicine to the Microbiome
Eligo Bioscience
—
September 2017
— 120 views
Stay updated :
Unsubscribe
Subscribe
Participate on our social stream.
Archives
2018
April
2
March
5
February
5
January
3
2017
December
1
November
5
October
2
September
3
July
3
June
1
May
3
April
1
February
1
January
2
2016
May
2
April
2
January
1
2015
September
1
Tags